Hemispherx Biopharma Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Philadelphia PA United States (1980)

Organization Overview

First Clinical Trial
1997
NCT00215813
First Marketed Drug
1989
interferon alfa-n3 (Alferon-N)
First NDA Approval
1989
interferon alfa-n3 (Alferon-N)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AIM ImmunoTech Inc. | Hemispherx Biopharma | HEM Research

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Colorectal Neoplasms (Phase 2)

Coronavirus Infections (Phase 2)

Encephalomyelitis (Phase 3)

Fatigue (Phase 3)

Fatigue Syndrome, Chronic (Phase 3)

HIV Infections (Phase 2)

HIV Seropositivity (Phase 2)

Influenza, Human (Phase 2)

Myalgia (Phase 3)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 11